Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Z Wang, L Yang, X Song - Frontiers in immunology, 2022 - frontiersin.org
GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …
Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys
Remdesivir 1 is an phosphoramidate prodrug that releases the monophosphate of
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …
COVID-19 drug discovery and treatment options
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
DTSEA: a network-based drug target set enrichment analysis method for drug repurposing against COVID-19
Y Su, J Wu, X Li, J Li, X Zhao, B Pan, J Huang… - Computers in Biology …, 2023 - Elsevier
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic is still wreaking havoc
worldwide. Therefore, the urgent need for efficient treatments pushes researchers and …
worldwide. Therefore, the urgent need for efficient treatments pushes researchers and …
Anti-SARS-CoV-2 biotherapeutics and chemotherapeutics: An insight into product specifications and marketing dynamics
Chemotherapeutics and biotherapeutics agents have been explored as a potential treatment
for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and …
for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and …
Cell and tissue specific metabolism of nucleoside and nucleotide drugs: case studies and implications for precision medicine
EE To - Drug Metabolism and Disposition, 2023 - ASPET
Many clinically used antiviral drugs are nucleoside or nucleotide analog drugs, which have
a unique mechanism of action that requires intracellular phosphorylation. This dependence …
a unique mechanism of action that requires intracellular phosphorylation. This dependence …
Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection–a single-center, retrospective, cohort study
K Kautsch, J Wiśniowska… - European Journal of …, 2024 - Springer
Despite 3.5 years of the SARS-CoV-2 pandemic, we still lack effective drugs against COVID-
19. The first and most widely used drug, remdesivir, has not yet been shown to be effective …
19. The first and most widely used drug, remdesivir, has not yet been shown to be effective …
Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116)
Q Cao, Y Ding, Y Xu, M Li, R Zheng, Z Cao, W Wang… - Frontiers of …, 2023 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic agents that target severe acute respiratory syndrome …
efforts to develop therapeutic agents that target severe acute respiratory syndrome …
Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation
MN Peralta-Moreno, Y Mena, D Ortega-Alarcon… - International Journal of …, 2024 - mdpi.com
The development of specific antiviral therapies targeting SARS-CoV-2 remains fundamental
because of the continued high incidence of COVID-19 and limited accessibility to antivirals …
because of the continued high incidence of COVID-19 and limited accessibility to antivirals …